Immunogenicity and efficacy of an anthrax/plague DNA fusion vaccine in a mouse model

FEMS Immunology and Medical Microbiology

Volumn 65, Issue 3, 2012, Pages 505-509

  Albrecht, Mark T ^a,e   Eyles, Jim E ^b,f   Baillie, Les W ^c,d   Keane Myers, Andrea M ^a  

^a NAVAL MEDICAL RESEARCH CENTER   (United States)

^b DEFENCE SCIENCE AND TECHNOLOGY LABORATORY   (United Kingdom)

^c CARDIFF UNIVERSITY   (United Kingdom)

^d UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^e U S DEPARTMENT OF HEALTH AND HUMAN SERVICES   (United States)

^f PFIZER INC   (United States)

Author keywords

Anthrax; DNA vaccine; Plague

Indexed keywords

ANTHRAX VACCINE; BACTERIAL ANTIGEN; DNA VACCINE; IMMUNOGLOBULIN G1;

AEROSOL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTHRAX; ARTICLE; BACILLUS ANTHRACIS; BACTERIAL GROWTH; BACTERIAL SPORE; BACTERIAL STRAIN; BACTERIAL SURVIVAL; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; FEMALE; GENE EXPRESSION; GENE GUN; GENE GUN IMMUNIZATION; IMMUNE RESPONSE; IMMUNOGENICITY; LETHAL GENE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PLAGUE; PRIORITY JOURNAL; YERSINIA PESTIS;

ANIMALS; ANTHRAX; ANTHRAX VACCINES; ANTIBODIES, BACTERIAL; ANTIGENS, BACTERIAL; BACILLUS ANTHRACIS; BACTERIAL PROTEINS; BACTERIAL TOXINS; BIOLISTICS; IMMUNIZATION; IMMUNOGLOBULIN G; MICE; PLAGUE; PLAGUE VACCINE; PORE FORMING CYTOTOXIC PROTEINS; RECOMBINANT FUSION PROTEINS; SPORES, BACTERIAL; SURVIVAL RATE; VACCINES, SYNTHETIC; YERSINIA PESTIS;

EID: 84863993331     PISSN: 09288244     EISSN: 1574695X     Source Type: Journal    
DOI: 10.1111/j.1574-695X.2012.00974.x     Document Type: Article

References (23)

1. Albrecht MT, Li H, Williamson ED et al. (2007) Human monoclonal antibodies against anthrax lethal factor and protective antigen act independently to protect against Bacillus anthracis infection and enhance endogenous immunity to anthrax. Infect Immun 75: 5425-5433.
2. Baillie LW (2009) Is new always better than old?: The development of human vaccines for anthrax. Hum Vaccin 5: 806-816.
3. Baillie L & Read TD (2001) Bacillus anthracis, a bug with attitude! Curr Opin Microbiol 4: 78-81.
4. Baillie LW, Huwar TB, Moore S et al. (2010) An anthrax subunit vaccine candidate based on protective regions of Bacillus anthracis protective antigen and lethal factor. Vaccine 28: 6740-6748.
5. Ballard JD, Collier RJ & Starnbach MN (1996) Anthrax toxin-mediated delivery of a cytotoxic T-cell epitope in vivo. P Nat Acad Sci USA 93: 12531-12534.
6. Beedham RJ, Turnbull PC & Williamson ED (2001) Passive transfer of protection against Bacillus anthracis infection in a murine model. Vaccine 19: 4409-4416.
7. Bennett AM, Phillpotts RJ, Perkins SD, Jacobs SC & Williamson ED (1999) Gene gun mediated vaccination is superior to manual delivery for immunisation with DNA vaccines expressing protective antigens from Yersinia pestis or Venezuelan Equine Encephalitis virus. Vaccine 18: 588-596.
8. Feltquate DM, Heaney S, Webster RG & Robinson HL (1997) Different T helper cell types and antibody isotypes generated by saline and gene gun DNA immunization. J Immunol 158: 2278-2284.
9. Griffin K, Bedford R, Townson K et al. (2005) Protective efficacy of a recombinant plague vaccine when co-administered with another sub-unit or live attenuated vaccine. FEMS Immunol Med Microbiol 43: 425-430.
10. Hermanson G, Whitlow V, Parker S et al. (2004) A cationic lipid-formulated plasmid DNA vaccine confers sustained antibody-mediated protection against aerosolized anthrax spores. P Nat Acad Sci USA 101: 13601-13606.
11. Livingston BD, Little SF, Luxembourg A, Ellefsen B & Hannaman D (2010) Comparative performance of a licensed anthrax vaccine versus electroporation based delivery of a PA encoding DNA vaccine in rhesus macaques. Vaccine 28: 1056-1061.
12. Lu Y, Friedman R, Kushner N et al. (2000) Genetically modified anthrax lethal toxin safely delivers whole HIV protein antigens into the cytosol to induce T cell immunity. P Nat Acad Sci USA 97: 8027-8032.
13. Mosmann TR & Coffman RL (1989) TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol 7: 145-173.
14. Price BM, Liner AL, Park S, Leppla SH, Mateczun A & Galloway DR (2001) Protection against anthrax lethal toxin challenge by genetic immunization with a plasmid encoding the lethal factor protein. Infect Immun 69: 4509-4515.
15. Riemenschneider J, Garrison A, Geisbert J et al. (2003) Comparison of individual and combination DNA vaccines for B. anthracis, Ebola virus, Marburg virus and Venezuelan equine encephalitis virus. Vaccine 21: 4071-4080.
16. Russell P, Eley SM, Hibbs SE, Manchee RJ, Stagg AJ & Titball RW (1995) A comparison of Plague vaccine, USP and EV76 vaccine induced protection against Yersinia pestis in a murine model. Vaccine 13: 1551-1556.
17. Sedegah M, Charoenvit Y, Minh L et al. (2004) Reduced immunogenicity of DNA vaccine plasmids in mixtures. Gene Ther 11: 448-456.
18. Shen HG, Zhou JY, Zhang X, Huang ZY, He JL & Yan Y (2009) Interference of porcine circovirus type 2 ORF2 immunogenicity by ORF1 and ORF3 mixed DNA immunizations in mice. Virology 393: 104-111.
19. Turnbull PCB (1991) Anthrax vaccines - past, present and future. Vaccine 9: 533-539.
20. Wang KY, Guo YJ, Zhang YL, Lv K & Sun SH (2007) Combined DNA vaccination against three animal viruses elicits decreased immunogenicity of a single plasmid in mice. Vaccine 25: 4429-4436.
21. Williamson ED, Vesey PM, Gillhespy KJ, Eley SM, Green M & Titball RW (1999) An IgG1 titre to the F1 and V antigens correlates with protection against plague in the mouse model. Clin Exp Immunol 116: 107-114.
22. Williamson ED, Eley SM, Stagg AJ, Green M, Russell P & Titball RW (2000) A single dose sub-unit vaccine protects against pneumonic plague. Vaccine 19: 566-571.
23. Williamson ED, Bennett AM, Perkins SD, Beedham RJ, Miller J & Baillie LW (2002) Co-immunisation with a plasmid DNA cocktail primes mice against anthrax and plague. Vaccine 20: 2933-2941.